BBX Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the BBX gene in a human near-haploid cell background. This polyclonal knockout pool provides a powerful loss-of-function model for investigating BBX-dependent transcriptional regulation and its role in key signaling networks. The heterogeneous nature of the polyclonal population captures a range of gene-disruption events, making it particularly suitable for pooled functional genomics screens, pathway dissection, and drug sensitivity profiling without the clonal bias inherent in monoclonal isolates.
The host cell line, HAP1, is a human chronic myeloid leukemia-derived near-haploid cell line originally derived from the male KBM-7 cell line. Its near-haploid karyotype significantly simplifies genetic manipulation and ensures highly efficient CRISPR/Cas9-mediated gene disruption, as most loci exist in a single copy. This characteristic, combined with its hematopoietic lineage origin, makes HAP1 an ideal model for studying myeloid leukemia biology, hematopoietic cellular processes, and general gene function. The cell line stably expresses a near-haploid chromosome complement, facilitating unambiguous genotype-phenotype correlations in knockout studies.
BBX encodes an HMG-box transcription factor that integrates inputs from multiple developmental and oncogenic pathways. Mechanistically, BBX binds to HMG-box DNA motifs and interacts with key signaling mediators, including ??-catenin (CTNNB1) in the Wnt pathway, RBPJ in the Notch pathway, and SMAD3 in the TGF-?? pathway. Upstream signals such as WNT3A, DLL4, and TGFB1 activate their respective cascades, leading to BBX recruitment to chromatin and subsequent regulation of downstream targets. Among its transcriptional targets are CCND1 (cyclin D1), which promotes cell cycle progression, and CDKN1A (p21), a cyclin-dependent kinase inhibitor. BBX also modulates apoptotic genes BCL2 and BAX, as well as feedback regulators like AXIN2. Through these interactions, BBX orchestrates gene expression programs controlling proliferation, differentiation, and survival.
In HAP1 cells, disruption of BBX perturbs the coordinated regulation of Wnt, Notch, and TGF-?? signaling outputs, leading to alterations in cell cycle kinetics, apoptosis sensitivity, and differentiation status. The near-haploid background ensures that even heterozygous disruptions result in a complete loss of functional alleles in most cells, providing a clean system to dissect BBX function. Given the HAP1 cell line??s myeloid leukemia origin, the BBX knockout model is particularly relevant for studying leukemogenesis and hematopoietic malignancies, while also serving as a versatile platform for interrogating BBX??s role in other cancers, such as neuroblastoma and colorectal cancer, and in developmental disorders.
This BBX knockout polyclonal cell population supports a wide range of applications, including functional genomics, high-content screening, and mechanistic studies of Wnt, Notch, and TGF-?? pathways. Typical assays include Western blotting for BBX protein loss, RT-qPCR quantification of CCND1 and CDKN1A transcript levels, RNA-seq transcriptome profiling, flow cytometric cell cycle analysis using propidium iodide, Annexin V/PI apoptosis assays, and Wnt luciferase reporter assays to assess pathway activity. Co-immunoprecipitation experiments can validate interactions with CTNNB1 or SMAD3, while drug sensitivity profiling enables target validation and therapeutic compound screening. Researchers are encouraged to contact Ascent Research for further information or to place orders.
